The growing concern of MDR/XDR bacteria in patients undergoing dialysis: a cross-sectional study

Authors

DOI:

https://doi.org/10.22141/2307-1257.14.2.2025.523

Keywords:

MDR, XDR, dialysis patients, chronic kidney disease

Abstract

Background. Dialysis patients are at heightened risk for multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacterial infections due to their vulnerability to infections and frequent exposure to healthcare environments. This study aims to determine the prevalence, risk factors, and antimicrobial resistance patterns of these pathogens to enhance patient care and infection control strategies. Materials and methods. This cross-sectional study was conducted at the Al-Hussein Teaching Hospital Dialysis Unit in Thi-Qar, Nasiriyah, Iraq, from September to December 2024, involving 121 dialysis patients. Data collected from participants included demographic information, comorbidities, and dialysis-related parameters. Microbiological analysis involved urine sample processing through bacterial culture, with bacterial identification and antimicrobial susceptibility testing performed using the VITEK 2 Compact system. Results. The mean age of the study population was 55.0 ± 16.6 years, with a higher proportion of males (52.9 %). Diabetes mellitus was the most common comorbidity, affecting 70 % of patients either alone or in combination with hypertension and cardiovascular disease. The culture positivity rate was 19.0 %, with E.coli being the most frequently isolated pathogen (65.2 %), followed by K.pneumoniae (21.7 %) and E.cloacae (13.1 %). Antimicrobial resistance testing revealed that 60 % of E.coli and all K.pneumoniae isolates were MDR, while 40 % of E.coli and 33.3 % of E.cloacae were XDR. A significant negative correlation was observed between dialysis duration and infection frequency (r = –0.2285, p = 0.0117), indicating a higher likelihood of infections during the initial year of dialysis therapy. Conclusions. The findings underscore the high prevalence of MDR/XDR bacterial infections among dialysis patients, particularly during the early stages of treatment. This highlights the urgent need for enhanced infection control measures, robust antimicrobial stewardship programs, and regular surveillance within dialysis facilities. Targeted interventions are essential to reduce infection-related morbidity and mortality among this vulnerable patient population.

Downloads

Download data is not yet available.

References

Francis A, Harhay MN, Ong ACM, et al.; American Society of Nephrology; European Renal Association; International Society of Nephrology. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024 Jul;20(7):473-485. doi: 10.1038/s41581-024-00820-6.

Chan RJ, Helmeczi W, Canney M, Clark EG. Management of Intermittent Hemodialysis in the Critically Ill Patient. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):245-255. doi: 10.2215/CJN.04000422.

Li PK, Chan GC, Chen J, et al. Tackling Dialysis Burden around the World: A Global Challenge. Kidney Dis (Basel). 2021 May;7(3):167-175. doi: 10.1159/000515541.

Apata IW, Kabbani S, Neu AM, et al. Opportunities to Improve Antibiotic Prescribing in Outpatient Hemodialysis Facilities: A Report From the American Society of Nephrology and Centers for Disease Control and Prevention Antibiotic Stewardship White Paper Writing Group. Am J Kidney Dis. 2021 May;77(5):757-768. doi: 10.1053/j.ajkd.2020.08.011.

Jihad M, Salih M. Microbial Detection and Antibiotic Susceptibility patterns of Clinical Isolates from Women with Urinary Tract Infection in AL-Nasiriyah City/Iraq. Univ Thi-Qar J Sci. 2024;11(1):45-54. doi: 10.32792/utq/utjsci/v11i1.1168.

Hanoon N. Prevalence of urinary tract infections among pregnant women in Iraq: meta-analysis study. University of Thi-Qar Journal of Science. 2024;11(2):1-7. doi: 10.32792/utq/utjsci/v11i2.1181.

World Health Organization (WHO). 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: WHO; 2024. 231 p.

US Centers for Disease Control and Prevention (CDC). Antimicrobial Resistance Threats in the United States, 2021-2022. Available from: https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html.

Guo S, Yang L, Zhu X, et al. Multidrug-resistant organism-peritoneal dialysis associated peritonitis: clinical and microbiological features and risk factors of treatment failure. Front Med (Lausanne). 2023 May 10;10:1132695. doi: 10.3389/fmed.2023.1132695.

AbuTaha SA, Al-Kharraz T, Belkebir S, Abu Taha A, Zyoud SH. Patterns of microbial resistance in bloodstream infections of hemodialysis patients: a cross-sectional study from Palestine. Sci Rep. 2022 Oct 26;12(1):18003. doi: 10.1038/s41598-022-21979-7.

Chesnaye NC, Ortiz A, Zoccali C, Stel VS, Jager KJ. The impact of population ageing on the burden of chronic kidney disease. Nat Rev Nephrol. 2024 Sep;20(9):569-585. doi: 10.1038/s41581-024-00863-9.

Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol. 2022 Jun;18(6):378-395. doi: 10.1038/s41581-022-00542-7.

Zhang S, Yang Z, Sun L, et al. Clinical observation and prognostic analysis of patients with klebsiella pneumoniae bloodstream infection. Front Cell Infect Microbiol. 2020 Nov 9;10:577244. doi: 10.3389/fcimb.2020.577244.

Murray EC, Marek A, Thomson PC, Coia JE. Gram-negative bacteraemia in haemodialysis. Nephrology Dialysis Transplantation. 2015 Jul;30(7):1202-1208. doi: 10.1093/ndt/gfv205.

Kanamori H, Weber DJ, Flythe JE, Rutala WA. Waterborne Outbreaks in Hemodialysis Patients and Infection Prevention. Open Forum Infect Dis. 2022 Feb 3;9(3):ofac058. doi: 10.1093/ofid/ofac058.

Qasim A, Salih HA. Isolation and identification of Klebsiella pneumonia from wound infections and study of the synergistic effect of carpenems and cefepime. University of Thi-Qar Journal of Science. 2024;11(2):136-141. doi: 10.32792/utq/utjsci/v11i2.1221.

Maharjan G, Khadka P, Siddhi Shilpakar G, Chapagain G, Dhungana GR. Catheter-Associated Urinary Tract Infection and Obstinate Biofilm Producers. Can J Infect Dis Med Microbiol. 2018 Aug 26;2018:7624857. doi: 10.1155/2018/7624857.

De Oliveira Júnior NG, Franco OL. Promising strategies for future treatment of Klebsiella pneumoniae biofilms. Future Microbiol. 2020 Jan;15:63-79. doi: 10.2217/fmb-2019-0180.

Holt RIG, Cockram CS, Ma RCW, Luk AOY. Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment. Diabetologia. 2024 Jul;67(7):1168-1180. doi: 10.1007/s00125-024-06102-x.

Kim EJ, Ha KH, Kim DJ, Choi YH. Diabetes and the Risk of Infection: A National Cohort Study. Diabetes Metab J. 2019 Dec;43(6):804-814. doi: 10.4093/dmj.2019.0071.

Corrêa HL, Deus LA, Nascimento DDC, et al. Concerns about the application of resistance exercise with blood-flow restriction and thrombosis risk in hemodialysis patients. J Sport Health Sci. 2024 Jul;13(4):548-558. doi: 10.1016/j.jshs.2024.02.006.

Downloads

Published

2025-06-29

How to Cite

Kadhem, N. S., & Atya, A. K. (2025). The growing concern of MDR/XDR bacteria in patients undergoing dialysis: a cross-sectional study. KIDNEYS, 14(2), 130–139. https://doi.org/10.22141/2307-1257.14.2.2025.523

Issue

Section

Original Articles